Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease.

about

Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease.

Item

http://www.wikidata.org/entity/Q40789562

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Lipoprotein-associated phospho ...... s with coronary heart disease.

@en

type

Item

label

Lipoprotein-associated phospho ...... s with coronary heart disease.

@en

prefLabel

Lipoprotein-associated phospho ...... s with coronary heart disease.

@en

P1476

Lipoprotein-associated phospho ...... s with coronary heart disease.

@en

P2093

Batya Sapir

http://www.w3.org/2001/XMLSchema#string

Michal Benderly

http://www.w3.org/2001/XMLSchema#string

Ofra Kalter-Leibovici

http://www.w3.org/2001/XMLSchema#string

Reuven Zimlichman

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

Effect of darapladib treatment on endarterectomy carotid plaque lipoprotein-associated phospholipase A2 activity: a randomized, controlled trial

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

Racial variation in lipoprotein-associated phospholipase A₂ in older adults.

Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers.

Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.

Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.

P304

219-224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/1354750X.2016.1171910

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Reuven Zimlichman

P577

2016-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27097870

http://www.w3.org/2001/XMLSchema#string

P921

lipoprotein